Lead Sponsor

University of Miami

Age

18 - 120 years

Sex

ALL

Healthy Volunteers

No

•≥ 18 years old with previously untreated, histologically confirmed Marginal Zone Lymphoma (non-gastric extranodal MZL, splenic MZL and nodal MZL) or gastric MZL that did not respond to antibiotic therapy given up to 6 months prior to enrollment, but not less than 2 months)
•Measurable and evaluable disease
•All stages are eligible
•Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 (Appendix B)
•Willing and able to provide written informed consent
•Women of childbearing potential must have a negative pregnancy test at study entry and must agree to use effective contraception while on treatment and for 6 months after treatment
•Life expectancy of at least 6 months

•Prior chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids, or systemic biologic anticancer therapy before beginning study treatment.
•≥ 25% lymphoma bone marrow involvement
•Platelet count \< 100,000 cells/mm³
•Neutrophil count \< 1,500 cells/mm³
•Known history of HIV infection
•Pregnant or lactating (pregnancy test is required for all female patients of childbearing potential)
•Woman of childbearing potential or sexually active man unwilling to use adequate contraceptive protection.
•Physical or mental condition that makes patient unable to complete specified follow-up assessments

Related studies

NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

NCT05294731 · B-cell Malignancy, Non-Hodgkin Lymphoma, and more

NCT06149286 · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

NCT05006716 · B-cell Malignancy, Marginal Zone Lymphoma, and more

NCT06026319 · Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, and more

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma